RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Xlife Sciences Stock

Xlife Sciences P/S 2025

Xlife Sciences P/S

61.86

Ticker

XLS.SW

ISIN

CH0461929603

WKN

A2PK6Z

As of Mar 6, 2025, Xlife Sciences's P/S ratio stood at 61.86, a -35.34% change from the 95.67 P/S ratio recorded in the previous year.

The Xlife Sciences P/S history

Xlife Sciences Aktienanalyse

What does Xlife Sciences do?

Xlife Sciences AG is a company active in the field of biotechnology. The company was founded in 2017 and is based in Switzerland. The main activity of Xlife Sciences AG is the identification and development of biotechnology products, particularly in the field of health sciences. The business model of Xlife Sciences AG is based on collaborations with leading scientists and research groups worldwide. The company identifies promising research areas and takes on the financing and development of projects until they are marketable. Xlife Sciences AG works closely with academic environments, universities, research institutes, venture capital firms, and other partners. Xlife Sciences AG specializes in three main divisions: Human Health, Agrifood, and Industrial Biotechnology. Under the Human Health division, the company develops drugs and therapies for various diseases and health problems. These include cancer, diabetes, cardiovascular diseases, infectious diseases, and autoimmune diseases. The Agrifood division of Xlife Sciences AG works on innovative solutions for agriculture and food production. This includes the development of plants that are resistant to pests and drought, as well as the development of foods with functional properties such as increased nutritional value or improved durability. The Industrial Biotechnology division of Xlife Sciences AG focuses on the development of biotechnological products for industrial use. This includes biofuels made from renewable raw materials and the production of biobased materials such as plastics and textiles. An example of a product developed by Xlife Sciences AG is a new drug against cancer. This drug was developed in collaboration with the University of Basel and has the potential to revolutionize cancer treatment. The effectiveness of the drug has already been proven in animal tests, and preparations for clinical trials are underway. Overall, Xlife Sciences AG aims to develop innovative technologies and products that improve people's lives while also being economically successful. The company relies on close cooperation with scientists, investors, and industry partners. Xlife Sciences AG has established itself as an important player in the biotechnology industry and continuously works to expand its range of products and services. Although the company is relatively young, it already has numerous promising projects in the pipeline and strives to develop innovative solutions for the challenges of our time in the future. Xlife Sciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Xlife Sciences's P/S Ratio

Xlife Sciences's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Xlife Sciences's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Xlife Sciences's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Xlife Sciences’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Xlife Sciences stock

What is the price-to-earnings ratio of Xlife Sciences?

The price-earnings ratio of Xlife Sciences is currently 61.86.

How has the price-earnings ratio of Xlife Sciences changed compared to last year?

The price-to-earnings ratio of Xlife Sciences has increased by -35.34% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Xlife Sciences high compared to other companies?

Yes, the price-to-earnings ratio of Xlife Sciences is high compared to other companies.

How does an increase in the price-earnings ratio of Xlife Sciences affect the company?

An increase in the price-earnings ratio of Xlife Sciences would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Xlife Sciences affect the company?

A decrease in the price-earnings ratio of Xlife Sciences would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Xlife Sciences?

Some factors that influence the price-earnings ratio of Xlife Sciences are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Xlife Sciences pay?

Over the past 12 months, Xlife Sciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Xlife Sciences is expected to pay a dividend of 0 CHF.

What is the dividend yield of Xlife Sciences?

The current dividend yield of Xlife Sciences is .

When does Xlife Sciences pay dividends?

Xlife Sciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Xlife Sciences?

Xlife Sciences paid dividends every year for the past 0 years.

What is the dividend of Xlife Sciences?

For the upcoming 12 months, dividends amounting to 0 CHF are expected. This corresponds to a dividend yield of 0 %.

In which sector is Xlife Sciences located?

Xlife Sciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Xlife Sciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Xlife Sciences from 3/6/2025 amounting to 0 CHF, you needed to have the stock in your portfolio before the ex-date on 3/6/2025.

When did Xlife Sciences pay the last dividend?

The last dividend was paid out on 3/6/2025.

What was the dividend of Xlife Sciences in the year 2024?

In the year 2024, Xlife Sciences distributed 0 CHF as dividends.

In which currency does Xlife Sciences pay out the dividend?

The dividends of Xlife Sciences are distributed in CHF.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Xlife Sciences

Our stock analysis for Xlife Sciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Xlife Sciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.